Brief: Avenue Therapeutics Enters Into Agreement With Annji Pharmaceutical To Develop And Commercialize Aj201, For Treatment Spinal And Bulbar Muscular Atrophy
02/03/2023 13:53
March 2 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS ENTERS INTO A TRANSFORMATIONAL LICENSE
AGREEMENT WITH ANNJI PHARMACEUTICAL TO DEVELOP AND COMMERCIALIZE
AJ201, A FIRST-IN-CLASS CLINICAL ASSET FOR THE TREATMENT OF
SPINAL AND BULBAR MUSCULAR ATROPHY
* UNDER AGREEMENT, ANNJI WILL RECEIVE UPFRONT PAYMENTS OF $3
MILLION
Source text for Eikon: ID:nGNX48q3p4
Further company coverage: ATXI.O
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary